Formulated zinc methionyl bST (sometribove, 50, 100, or 150 mg) was administered as a single treatment once every 2 wk or as two equal treatments oncelweek to evaluate the efficacy of prolonged release delivery of bovine somatotropin (bST) in finishing lambs. Feed conversion during the 6-wk treatment period was improved 9 and 19% in lambs that received treatments once and twice/2 wk, respectively ( P < .05), and the responses to differing doses were similar within a dosing frequency ( P > .05). Carcass musc1e:fat ratio indicators generally were affected in a dose-related manner and were independent of frequency of administration. For example, fat thickness was 17, 30, and 42% lower than control in lambs that received 50, 100, and 150 mg of formulated sometribovel2 wk, respectively ( P < .05).
Introduction
Daily injection of somatotropin ( ST) has improved growth performance and carcass leanness of finishing lambs under a variety of conditions (Rosemberg et al., 1989; Zainur et al., 1989; Beermann et al., 1990) . The development of recombinant technology has facilitated the production of large quantities of ST and increased the possibility of its use to improve productivity. The practical value of ST can be further enhanced by the use of prolonged-release systems. In lambs, the use of an oil vehicle improved circulating ST profile (increased area under the curve) but did not enhance biological response to ST (Muir et al., 1983; Johnsson et al., 1987) . A prolonged-release system of some-J . h i m . Sci. 1994 Sci. . 72:2544 Sci. -2551 tribove (zinc methionyl bovine ST) has been developed for use in dairy cows to increase milk production . Daily injection of sometribove, the ST in this prolonged-release system, elicited growth performance and carcass composition responses equivalent to those t o ovine ST (McLaughlin et al., 1993b) . Thus, in the present study, the ability of bST in this prolonged-release system to improve growth performance and carcass leanness in finishing lambs was evaluated. The objectives were to determine optimal treatment frequency (once or twice/2 wk) and dosage (50, 100, or 150 mgl2 wk). over slatted floors. Lambs were gradually adapted over a 3-wk period t o a pelleted commercial lamb finisher diet formulated to contain 16% protein on a DM basis. The lambs were given ad libitum access to feed. Samples of the diet were taken weekly and composited every 3 wk for nutrient analysis according to AOAC methods (1990) (Livestock Nutrition Laboratory Services, Columbia, MO) . Results of the analyses are summarized in Table 1 . Each pen was equipped with a feeder and water nipple from which fresh water was continuously available. The study was conducted during summer months and either evaporative coolers or fans were used to maintain the temperature below 27°C.
Treatments and Experimental Design. Seven treatments included in this study were control (no injection), 25, 50, or 75 mg of sometribove (methionyl bovine somatotropin) in a prolonged-release, oil-based formulation (formulated sometribove, lot numbers 9OK29-30 and 9OL22-50, Monsanto, St. Louis, MO) administered weekly or 50, 100, or 150 mg of formulated sometribove administered once every 2 wk. One-milliliter syringes equipped with 2.5-cm, 16-gauge needles were filled to deliver the appropriate volume of formulated sometribove. The treatments were injected S.C. 5 cm t o the side of the nape of the neck on alternating right or left sides.
Two separate studies with a total of 112 wethers and 105 ewes were conducted. Lambs within each part were selected on the basis of health and BW and were assigned t o one of the seven treatment groups above according to a randomized block design that included study, sex, barn, start date, and weight as blocking (McLaughlin et al., 1991 (McLaughlin et al., , 1993a . Intraassay and interassay CV for insulin were 11.1 and 5.3%, respectively. Intraassay and interassay CV for IGF-I were 7.9 and 9.1%, respectively. Serum bST was measured by radioimmunoassay using an antiserum raised in rabbits (lot number R608-6/83, Monsanto) that cross-reacted 37% with ovine ST. Sometribove (Monsanto) was used as the standard and radiolabel and was radioiodinated by a cholamine-T procedure. Bound label was precipitated by goat anti-rabbit gamma globulin (Linco Research, St. Louis, MO) and polyethylene glycol (Sigma Chemical, St. Louis, MO). Pooled, untreatedcontrol sheep serum was spiked with several different levels ranging from .5 ng/mL to 20 ng/mL and total percentage recovery was 99%. Spiked sheep serum was diluted with assay buffer up to 1:14 dilution. Parallelism was met with an intercept of 1.507 and slope of 1.017, F-value of 553. The line met the parallelism standard ( .46), Intraassay and interassay CV for bST were 10.3 and 6.1%, respectively.
Carcass Measurements. Lambs were slaughtered and hot carcass weights were recorded. The carcasses were chilled and, on the following day, the carcasses were yield-and quality-graded according to USDA standards (Boggs and Merkel, 1984) . To enable statistical analysis of yield and quality grade traits, numerical values were assigned to alpha descriptions. Conformation, quality grade, and leg score were assigned a value of 15 for Prime plus and descending numbers for each grade lower (e.g., Prime average = 14, etc.). Maturity, fat streaking, and firmness scores were assigned numbers starting with higher numbers for most mature, abundant streaking, and extremely firm descriptions, respectively. The longissimus muscle was traced with a planimeter to obtain area. Percentage and weight of carcass fat and muscle were calculated using modified formulas derived by Latham et al. (1966 and personal communication) . It is recognized that the formulas were based on non-bSTtreated lambs, but their use provides an estimate of effects on carcass composition.
Data Analysis. Growth performance and carcass data were analyzed using the GLM procedures of SAS (1989) . Data for each study were combined and were subjected to a preliminary test of treatment x study interaction in a fixed-effects model. When the interaction was significant ( P < .25), a mixed-model analysis of variance was used with treatment, barn, and start weight block as fixed effects and study and treatment x study interaction as random effects. Initial BW was used as a covariate for performance and carcass data. When the treatment x study interaction was not significant ( P > .25), a reduced mixed model that ignores the interaction was used. When treatment effects were significant ( P < .05), least squares treatment means were tested for linear and quadratic effects of dose within and between treatment frequency (once or twicef2 wkj and were compared using a LSD procedure. The reported least squares means and their differences are from the mixed-model equations and are applied to a broader inference space (i.e., the coefficients of the random parameters are set to zero) (SAS, 1992) . Clinical chemistry data were analyzed a t each time point using the same GLM procedures. Because there was a treatment effect on the d-1 urea nitrogen concentrations, d-1 values were used as a covariate in the analysis of d-43 urinary concentrations.
Injection Site Scores. Injection sites were palpated biweekly and scored according t o the scoring system 0 = no evidence of injection, 1 = raised area of less than 1 cm, 2 = raised area approximately 1 cm, and 3 = raised area greater than 1 cm.
Results
Health Summary. Data from five lambs were removed from all analyses. One ewe (75 mg of sometribove/wk) was killed on d 6 because her leg was broken when caught in the pen divider. Two wethers (50 mg of sometribovefwk and f2 wk) were removed as a consequence of an intestinal prolapse through a rectal tear (died) or severely prolapsed rectum (killed). Two wethers ( 7 5 mg of sometribovefwk and 150 mg of sometribovef2 wk) that had urinary calculi were also removed.
Performance. Only lambs with severe health problems were removed from the study during the treatment period. However, there were several lambs that were examined throughout the study for poor growth as a routine procedure but for which no cause could be found. In these lambs, feed conversions were as high as 20.0 and including their results in performance data disproportionately affected means. A feed conversion cut-off value of 11.0 was selected because it was one unit above two standard deviations above the mean for all observations (7.12 + 2.96). A total of 10 lambs were excluded from the analysis using this method (see Table 2 ). Because the treatment x study interaction term was significant ( P < .25) for growth rate and feed intake, this interaction was included in the mixed model for all three growth performance traits. Growth rate was numerically 22% higher compared with control for lambs that received 25 or 50 mg of sometribove/wk (Table 2) . Feed conversion responses were greater in lambs that received sometribove twice rather than once/2 wk ( P < .05). The maximum feed conversion improvement was 20%, observed in lambs that received 50 mg of sometribove/wk.
Carcass Evaluation. Carcass evaluation data are summarized in Table 3 . Specific data for some traits are missing because lambs were too light and not processed appropriately to collect information, hot weights were missing or unreadable, carcasses were processed before all measurements were recorded, or longissimus muscle area tracings were lost. Additionally, calculations including these traits could not be made. Number of lambs in groups of traits are indicated in the tables.
There were treatment x study interactions for live and hot weights ( P < .25); using the mixed-model analysis, there were no effects of treatment. Dressing percentage was lower than control in all groups that aLargest standard error of least squares treatment means. bExcludes lambs with health problems (see text) and lambs with feed eEciencies > 11.0. Numbers of lambs with feed efficiencies > 11.0 were 1 in the control group, 1,2, and 1 in the 25,50, and 75 mg of sometribove/wk groups, and 2 and 3 in the 100 and 150 mg of sometribovei2 wk groups.
c.d,eMeans within a row lacking a common superscript differ ( P < .05). bKP = kidney and pel\<c. d15 = Prime+, 14 = Prime", 13 = Prime-. e7 = slight+, 6 = slight", 5 = slight-. f12 = tends to be firm, 11 = moderately firm, 10 = tends to be moderately firm.
iJ,k,l.mMeans within a row lacking a common superscript differ ( P < ,051.
received sometribove weekly and in lambs that received 100 mg of sometribove/2 wk ( P < .05).
There was a treatment x study interaction for all quality grade traits ( P < .25) and, using the mixed model of analysis, there were no effects of treatment on maturity, conformation, fat streaking, or quality grade. Firmness was "tends to be firm" (score of 12) for controls and "moderately firm" (score of 11) for lambs that received higher doses of sometribove ( P < .05).
Among yield grade measures, treatment x study interaction was significant only for kidney and pelvic (KP) fat percentage and weight. Fat thicknesses for all sometribove treatment groups were lower than those for the control group ( P < .05). Fat thickness was lower in a linear manner among lambs that received treatments either once or twice12 wk. Fat thickness was a maximum of 46% lower than control in lambs that received 150 mg of sometribove/2 wk, and the change was similar across lambs that received treatments once or twice12 wk ( 3 1 vs 29%, respectively). Leg conformation was a maximum of one-half unit higher within the Choice plus range in lambs that received 50 mg of sometribovel2 wk ( P < .05). The KP fat (percentage and weight) differed from control in all sometribove-treated lambs ( P < .05). The KP fat percentage and weight were lowest at the highest doses in lambs that received sometribove once or twice12 wk. The KP fat percentage was numerically lower in lambs that received sometribove twice rather than once/2 wk (average of 38 vs 26%). Similarly, KP fat weight was numerically lower in lambs that received sometribove twice rather than once/2 wk (average 39 vs 27%).
Yield grade, whether based on fat thickness, leg conformation score, percentage of KP fat (old), or backfat thickness ( new 1, differed for all sometribove groups compared with control ( P < . 0 5 ) . The improvements in yield grade (old and new) were linear and quadratic for lambs that received treatments once and twice/2 wk, respectively, and were of similar magnitude for both groups. The largest improvement in yield grade was observed in lambs that received 150 mg of sometribovel2 wk. Carcass composition responses are summarized in Table 4 . Few carcass composition traits had treatment x study interactions. Thus, all were analyzed in the reduced model without the interaction. Percentage and weight of retail cuts were calculated using formulas based on old and new yield grades. Percentage of retail cuts was higher in all sometribove 
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treatment groups compared with control using both old and new system calculations ( P < .05). Maximum changes in percentage of retail cuts relative to control were 5 and 3% for lambs that received 150 mg of sometribovel2 wk in old and new systems, respectively, and the responses were similar in lambs that received the same dose once or twice12 wk. However, weight of retail cuts was not affected by treatment regardless of system used.
Calculations used to estimate carcass composition indicated lower fat and higher muscle associated with treatment. Percentages of carcass fat, muscle, and bone for all sometribove treatment groups differed from control, and the maximum responses were observed in lambs that received 150 mg of sometribovei2 wk ( P < .05). Among lambs that received treatment twice12 wk responses were similar for 50 and 75 mg of sometribove doses, whereas among lambs that received treatment once/:! wk the magnitude of responses was greater with increasing sometribove dose.
Among weight of carcass components, only fat weight was affected by sometribove treatment. Fat weight of all sometribove-treated lambs was lower than that of controls ( P < .05). Fat weight was lowest compared with control in lambs that received 150 mg of sometribovel2 wk. Responses did not differ consistently with number of treatments12 wk. Muscle weight was numerically a maximum of .7 kg higher than control in lambs that received 150 mg of sometribovel2 wk.
ClinicaI Chemistvy. Clinical chemistry responses to sometribove treatment are summarized in Table 5 . There was a treatment x study interaction ( P < .25) on d 43 for all hormones and metabolites except UN. Thus, treatment x study interaction was included in the mixed-model analysis of variance. Serum concentrations of bST on d 1 (not shown) were 10-to 100-fold those observed in untreated lambs in previous studies ( P < .05, McLaughlin et al., 199313) .
The average value was 50 ng/mL, with a range of 0 to > 400 ng/mL. Repeat assays confirmed these values, which occurred in d-1 samples of both studies. Investigation of all details of sampling and assay procedures did not reveal a reason for these abnormally high values. Among lambs that received sometribove twicei2 wk, d-43 bST concentrations were linearly related to dose level. Circulating bST concentrations a t the highest dose were fourfold those of control lambs. Among lambs that received treatments once/2 wk, the highest value was in lambs that received 100 mg of sometribove/2 wk. No treatment effects on relative bST binding were observed.
Plasma IGF-I on d 43 was higher than control in all lambs that received sometribove twice/2 wk but not in those that received it once/:! wk ( P < .05). Concentrations of IGF-I were higher in lambs that received each of the same 2-wk doses when they were administered twice rather than once/2 wk. Concentration of IGF-I was a maximum of 140% higher than control for lambs that received 75 mg of sometribove/wk. Serum insulin concentrations on d 43 were related to sometribove dose in lambs that received 50 or 75 mg of sometribove/wk but were not affected in lambs that received treatments once/:! wk ( P < .05). Insulin concentration was a maximum of ninefold higher than control in lambs that received 75 mg of sometribove/ wk.
Plasma glucose concentrations on d 43 were related to dose in lambs that received 50 or 75 mg of sometribove/wk but were not affected in lambs that received treatments once/2 wk ( P < .05). Glucose concentrations were a maximum of 84% higher than control in lambs administered the highest dose.
There was a treatment effect on d-1 serum UN concentrations ( P < .05). Therefore, d-1 concentration was used as a covariate in the analysis of d-43 UN concentrations. The UN concentrations were not affected in lambs that received one treatment/=! wk and were lower with increasing dose in lambs that received two treatmentd2 wk ( P < .05). The UN concentration was a maximum of 25% lower in lambs that received 75 mg of sometribove/wk.
Injection Site Scores. Injection sites of lambs
treated with sometribove were scored by palpating the area under the fleece biweekly. There was only one injection site with one dimension larger than 1 cm ( 2 cm x .25 cm). The site was present in a lamb treated with 150 mg of sometribove/2 wk at 2 wk and injection site score was normal at 4 wk. Generally, the number of detectable injection sites was higher in lambs that received sometribove weekly compared with biweekly. Few lambs had detectable injection sites for two consecutive scoring periods. A raised area approximately 1 cm in diameter, representing the most recent injection site, was cut out of most of the carcasses from lambs receiving sometribove.
Discussion
The results of this study have demonstrated that a prolonged release formulation of bST (sometribove) can improve growth performance and carcass composition in lambs. The directions and magnitudes of responses were similar to those reported previously in response to daily injection of ST (Johnsson et al., 1985; Zainur et al., 1989; Beermann et al., 1990; Pel1 et al, 1990; Bass et al., 1992; McLaughlin et al., 1993a,b) . Generally, growth performance was affected more in lambs that received sometribove with the higher frequency and responses were not dose-related. In contrast, most effects of sometribove treatment on carcass composition were independent of treatment frequency and were dose-related.
Performance and carcass composition effects of bST have generally been related to dose when multiple doses have been administered by daily injection (Johnsson et al., 1987; Sinnett-Smith et al., 1989; Zainur et al., 1989; Bass et al., 1992; McLaughlin et al., 1993a) . However, in some studies, growth performance was less at higher doses than a t lower doses of bST, whereas carcass composition effects were doserelated up to the highest doses (Sinnett-Smith et al., 1989; Bass et al., 1992 , McLaughlin et al., 1993a . In fact, Johnsson et al. ( 1987) observed dose-related effects on carcass composition in the absence of effects on growth performance. It is possible that even at the lowest doses tested in the present study the maximum growth response was elicited, whereas the carcass components were able to respond more to higher doses.
One of the objectives of this study was to evaluate efficacy based on treatment frequency. Effects of formulated sometribove on growth rate (not significant) and feed efficiency were greater with more frequent administration and the responses to the higher frequency were more similar to those reported by others administering similar doses by daily injection. The conclusion that more frequent administration elicited better performance was also made in pigs that received four vs one injectiod4 d (Evock et al., 1992) .
In contrast to performance responses, carcass responses in the present study generally were doserelated, as observed in studies in which lambs received ST by daily injection (Johnsson et al., 1987; Zainur et al., 1989; Bass et al., 1992) but were generally independent of dosing frequency. For example, in the present study, decreases in fat thickness in response to formulated sometribove were similar to those reported for equivalent oST or bST doses in other studies (Johnsson et al., 1987; Sinnett-Smith et al., 1989; Zainur et al., 1989; Beermann et al., 1990) . However, the decreases in backfat thickness were less than those in response to daily injection of the equivalent dose ( 4 mg/d) of sometribove (approximately 30%, McLaughlin et al., 1993a,b) . Reduced growth performance and carcass composition responses were also observed in pigs receiving pST by continuous release from a 6-wk implant compared with daily injection of the same dose on a per-day basis (Azain et al., 1992) .
Percentage and weight of KP fat were among the few carcass traits that were affected by frequency of treatment. They were lower when formulated sometribove was administered twice/2 wk rather than once/ 2 wk. In contrast, another indicator of fat composition, backfat thickness, was unaffected by treatment frequency. If internal fat depots are more responsive than external fat depots t o short-term changes in metabolism, more frequent injections (twice vs once/2 wk) would be predicted t o have a greater effect on KF' fat than on backfat.
The formulation of sometribove used in the present study was designed to increase ST concentrations for a 2-wk period. In cows (Eppard et al., 1993) and lambs (data not shown) that received formulated sometribove, circulating bST concentrations gradually increased from d 1 to approximately d 8 after injection, then gradually declined almost to pretreatment concentrations by d 14. It is important to note in the present study that the concentrations were measured 14 and 7 d after treatment for lambs that received treatments once and twice12 wk, respectively. Thus, any conclusions regarding treatment effects are based on the minimum changes that one could expect. The fact that bST concentrations were related to total dose but independent of dosing frequency paralleled the carcass responses but was in contrast to the performance responses, which were independent of dose and related to dosing frequency.
Others have also shown that growth performance may not be directly related to circulating bST concentrations. For example, average oST concentrations in lambs that received four daily doses of 10 pgl kg of human growth hormone releasing-factor were one-fifth those in lambs that received daily doses of 40 pg/kg of oST, but growth performance and carcass composition changes were generally equivalent (Beermann et al., 1990) . Additionally, olive oil used as a vehicle for either oST or bST increased the time that plasma ST concentrations were elevated but improved growth only slightly (Muir et al., 1983) or did not affect growth or carcass composition compared with buffer used as a vehicle (Johnsson et al., 1987) .
Although bST concentrations were higher than control in all lambs that received formulated sometribove, the concentration of other hormones and metabolites measured on d 43 were affected only in lambs that received treatments twice12 wk. However, circulating concentrations of other hormones and metabolites gradually increased to d 8 and then declined toward baseline in lambs that received a higher dose (200 mg of formulated sometribove/2 wk) in another study (data not shown). Thus, on d 43, at the end of the third 14-d cycle, concentrations would be expected to be near baseline. Changes in hormones and metabolites observed in lambs that received formulated sometribove twice/2 wk were generally similar in direction but smaller in magnitude than those observed in lambs that received bST (including sometribove) by daily injection on an equivalent milligradday basis (Johnsson et al., 1987; Zainur et al., 1989; Beermann et al., 1990; Pel1 et al, 1990; Bass et al., 1992; McLaughlin et al., 1993a,b) .
Maximum growth responses were observed in lambs that received 50 mg of sometribove/wk dose, and the maximum carcass responses were observed in lambs that received 150 mg of sometribovel2 wk dose. Although the feed conversion response to 50 mg of sometribovelwk did not differ from that t o the other doses administered twice every 2 wk, the response was twice that to the same dose administered once12 wk.
Maximum carcass value would be realized in lambs that received 150 mg of sometribove/2 wk because the yield grade (new) was improved more than one unit and the carcass weight (with KP fat) was reduced only .2 kg. In addition, the cutout value of the carcass of lambs that received 150 mg of sometribovel2 wk would be increased because the weight of retail cuts was increased .3 kg and the weight of muscle was increased .7 kg. Thus, formulated sometribove significantly improved growth performance and carcass leanness in finishing lambs.
Implications
Daily injection of somatotropin increases efficiency of production of lamb with more muscle and less fat, but the method of administration is not practical in commercial lamb-raising facilities. This study demonstrated that a prolonged-release formulation of bovine somatotropin administered weekly or once every 2 wk improved growth performance and increased carcass leanness. The use of somatotropin in a prolongedrelease formulation in commercial facilities could benefit the producer and provide lamb to the consumer that has more desirable characteristics and that is less costly to produce.
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